FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
| Autor: | Lena Specht, Francesco d'Amore, Anne-Marie Boesen, Annika Loft, Martin Hutchings, Thora Buhl, Anne Kiil Berthelsen, Simon Buus, Susanne Keiding, Lars Møller Pedersen, Jesper Jurlander, Mads Hansen |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Oncology
BEACOPP Adult Male medicine.medical_specialty Adolescent medicine.medical_treatment Immunology Biochemistry Disease-Free Survival Extranodal Disease Fluorodeoxyglucose F18 Predictive Value of Tests Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Progression-free survival Treatment Failure Stage (cooking) neoplasms Survival analysis Aged business.industry Cell Biology Hematology Middle Aged medicine.disease Prognosis Chemotherapy regimen Hodgkin Disease Survival Analysis Lymphoma carbohydrates (lipids) Predictive value of tests Positron-Emission Tomography Regression Analysis Female business Nuclear medicine |
| Zdroj: | Hutchings, M, Loft, A, Hansen, M, Pedersen, L M, Buhl, T, Jurlander, J, Buus, S, Keiding, S, D'Amore, F, Boesen, A-M, Berthelsen, A K & Specht, L 2006, ' FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. ', Blood, vol. 107, no. 1, pp. 52-9 . https://doi.org/10.1182/blood-2005-06-2252 |
| ISSN: | 0006-4971 |
| DOI: | 10.1182/blood-2005-06-2252 |
| Popis: | Risk-adapted lymphoma treatment requires early and accurate assessment of prognosis. This investigation prospectively assessed the value of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose (FDG-PET) after two cycles of chemotherapy for prediction of progression-free survival (PFS) and overall survival (OS) in Hodgkin lymphoma (HL). Seventy-seven consecutive, newly diagnosed patients underwent FDG-PET at staging, after two and four cycles of chemotherapy, and after completion of chemotherapy. Median follow-up was 23 months. After two cycles of chemotherapy, 61 patients had negative FDG-PET scans and 16 patients had positive scans. Eleven of 16 FDG-PET–positive patients progressed and 2 died. Three of 61 FDG-PET–negative patients progressed; all were alive at latest follow-up. Survival analyses showed strong associations between early FDG-PET after two cycles and PFS (P < .001) and OS (P < .01). For prediction of PFS, interim FDG-PET was as accurate after two cycles as later during treatment and superior to computerized tomography (CT) at all times. In regression analyses, early interim FDG-PET was stronger than established prognostic factors. Other significant prognostic factors were stage and extranodal disease. Early interim FDG-PET is a strong and independent predictor of PFS in HL. A positive early interim FDG-PET is highly predictive of progression in patients with advanced-stage or extranodal disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|